Excess body weight linked to increased risk for PCa recurrence

Article

Excess body weight may be associated with an increased risk for cancer recurrence in men with clinically localized prostate cancer, according to a study presented at the American Association for Cancer Research annual meeting in Chicago.

Excess body weight may be associated with an increased risk for cancer recurrence in men with clinically localized prostate cancer, according to a study presented at the American Association for Cancer Research annual meeting in Chicago.

"Men diagnosed with early-stage prostate cancer and who have excess body weight as indicated by a higher-than-normal body mass index have an increased risk for cancer recurrence after treatment," said study author Vincent L. Freeman, MD, MPH, of the School of Public Health at the University of Illinois, Chicago.

Dr. Freeman and colleagues examined body mass index and risk for cancer recurrence based on PSA level, physical exam, and prostate cancer biopsy results in 119 men who were awaiting surgery for clinically localized prostate cancer.

The results showed that the risk for cancer recurrence increased with increasing BMI. Men in the upper quartile for BMI were nearly eight times more likely to have prostate cancers that had a moderate to high risk for recurrence after treatment compared with men in the lower quartile. Men in the upper-middle and lower-middle quartiles for BMI were 6.5 times and 3.5 times more likely to have a moderate-to-high recurrence risk, respectively.

"The association was not limited to obese men; even being just overweight based on BMI was associated with an increased risk for prostate cancer recurrence," Dr. Freeman said.

The study was funded by the National Institutes of Health/National Cancer Institute.

Go back to this issue of Urology Times eNews.

Related Content

PSA screening cuts deaths by 29% in large European trial

Circumcision may reduce prostate risk

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.